Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Phase of Trial: Phase I/II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs Bavituximab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- 07 Sep 2017 According to a Peregrine Pharmaceuticals media release, National Comprehensive Cancer Network (NCCN) is responsible for oversight and monitoring of this and other two clinical studies (CTP700276381 and CTP276389) through the research grant.
- 07 Sep 2017 According to a National Comprehensive Cancer Network media release, first patient has been dosed.
- 16 Jun 2017 Status changed from not yet recruiting to recruiting.